We are a clinical-stage biotechnology company pioneering the treatment of cancers with a technology platform that allows the direct delivery of immunotherapeutic payloads within the tumor microenvironment. Intrinsic resistance significantly reduces the effectiveness of most cancer treatments, including leading-edge technologies such as checkpoint inhibitors and CAR-T cell therapies. Our delivery system takes advantage of a subset of tumor-associated macrophages called TEMs (Tie-2 expressing monocytes) which normally have an affinity for and travel to tumors, and turns them into a “Trojan Horse” to deliver an immunotherapeutic payload within tumors, where it can steer the natural immune responses towards anti-cancer-combat mode. Our leading product candidate has moved into Phase l/IIa clinical trials in glioblastoma and is poised to impact other hard-to-treat cancer types.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Internationally (various countries)
We were founded by Ospedale Raffaele Hospital (OSR), Milan, Pierluigi Paracchi (co-founder), Luigi Naldini (co-founder) and Bernhard Gentner (co-founder) in 2015 to develop first in class cell and gene therapies for cancer. We leverage the vast experience in cell and gene therapy of the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) a world leading cell and gene therapy research institution at the forefront of developing therapies for rare diseases that is a joint venture between OSR and Telethon. We maintain strong links with SR-Tiget and benefit from exclusive options on the Intellectual Property (IP) originated by the preclinical programs conducted in SR-Tiget laboratories and relating to our core science. Since its founding, Genenta has raised €33.6 million in three separate rounds of financing.